RBBP7: A Potential Drug Target Or Biomarker for Cancer (G5931)
RBBP7: A Potential Drug Target Or Biomarker for Cancer
RBBP7 (RB binding protein 7), also known as chromatin remodeling factor and transcript variant 2, is a protein that plays a crucial role in the regulation of gene expression in the cell. It is a member of the RBBP7 gene family, which is known for its involvement in various cellular processes, including chromatin remodeling, gene expression, and cell signaling.
The RBBP7 protein is highly expressed in various tissues and organs, including brain, heart, liver, and muscle. It is also highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that RBBP7 may be a potential drug target or biomarker for these cancers.
Drugs that target RBBP7 have the potential to disrupt its normal function and cause various cellular and molecular changes. For example, inhibitors of RBBP7 have been shown to inhibit the growth and survival of cancer cells, and to cause various cellular apoptosis.
In addition to its potential as a drug target, RBBP7 is also a potential biomarker for various types of cancer. Its high expression in various types of cancer makes it a promising candidate for use as a diagnostic or prognostic marker.
Understanding the biology of RBBP7 and its potential as a drug target or biomarker is the focus of ongoing research in the scientific community. Researchers are studying the various functions of RBBP7, including its role in gene expression, DNA replication, and cell signaling.
One of the main goals of research into RBBP7 is to understand its role in cancer progression and treatment. Studies have shown that RBBP7 is involved in various cellular processes that are associated with cancer growth and progression, including the regulation of cell cycle progression, the formation of nuclear stress, and the regulation of apoptosis.
In addition to its role in cancer progression, RBBP7 is also involved in the regulation of gene expression. Studies have shown that RBBP7 plays a role in the regulation of various gene expression pathways, including those involved in cell signaling, DNA replication, and cell cycle regulation.
The identification of RBBP7 as a potential drug target or biomarker has significant implications for the development of new cancer therapies. By targeting RBBP7, researchers may be able to disrupt its normal function and inhibit its role in cancer growth and progression.
Conclusion
RBBP7 is a protein that plays a crucial role in the regulation of gene expression in the cell. Its high expression in various tissues and organs, as well as its involvement in various cellular processes, make it a potential drug target or biomarker for various types of cancer.
While further research is needed to fully understand the role of RBBP7 in cancer progression and treatment, its potential as a drug target or biomarker is an exciting area of 鈥嬧?媟esearch that has the potential to lead to new and effective cancer therapies.
Protein Name: RB Binding Protein 7, Chromatin Remodeling Factor
Functions: Core histone-binding subunit that may target chromatin remodeling factors, histone acetyltransferases and histone deacetylases to their histone substrates in a manner that is regulated by nucleosomal DNA. Component of several complexes which regulate chromatin metabolism. These include the type B histone acetyltransferase (HAT) complex, which is required for chromatin assembly following DNA replication; the core histone deacetylase (HDAC) complex, which promotes histone deacetylation and consequent transcriptional repression; the nucleosome remodeling and histone deacetylase complex (the NuRD complex), which promotes transcriptional repression by histone deacetylation and nucleosome remodeling; and the PRC2/EED-EZH2 complex, which promotes repression of homeotic genes during development; and the NURF (nucleosome remodeling factor) complex
The "RBBP7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RBBP7 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
RBBP8 | RBBP8NL | RBBP9 | RBCK1 | RBFA | RBFOX1 | RBFOX2 | RBFOX3 | RBIS | RBKS | RBL1 | RBL2 | RBM10 | RBM11 | RBM12 | RBM12B | RBM14 | RBM14-RBM4 | RBM15 | RBM15-AS1 | RBM15B | RBM17 | RBM17P1 | RBM18 | RBM19 | RBM20 | RBM22 | RBM22P1 | RBM23 | RBM24 | RBM25 | RBM26 | RBM26-AS1 | RBM27 | RBM28 | RBM3 | RBM33 | RBM34 | RBM38 | RBM39 | RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5 | RBP7 | RBPJ | RBPJL | RBPJP2 | RBPMS | RBPMS-AS1 | RBPMS2 | RBSN | RBX1 | RC3H1 | RC3H2 | RCAN1 | RCAN2 | RCAN3 | RCAN3AS | RCBTB1 | RCBTB2 | RCC1 | RCC1L
